World Journal of Dentistry

Register      Login

VOLUME 13 , ISSUE 6 ( November-December, 2022 ) > List of Articles


Formulation and Evaluation of Antimicrobial Activity of Boswellia serrata Roxb. Gel against Periodontal Pathogens: An In Vitro Study

Shweta Sonkusle, Jyoti I Pattanashetti, Nagaraj B Kalburgi, Varsha Singh, Kavita A Patil

Keywords : Disk diffusion test, Gingivitis, Local drug delivery, Minimum inhibitory concentration, Periopathogens

Citation Information : Sonkusle S, Pattanashetti JI, Kalburgi NB, Singh V, Patil KA. Formulation and Evaluation of Antimicrobial Activity of Boswellia serrata Roxb. Gel against Periodontal Pathogens: An In Vitro Study. World J Dent 2022; 13 (6):600-605.

DOI: 10.5005/jp-journals-10015-2125

License: CC BY-NC 4.0

Published Online: 26-08-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Aim: To assess the antimicrobial activity of Boswellia serrata Roxb. in the form of gel against Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum, and Tannerella forsythia. Materials and methods: The bacterial strains of selected periopathogens were cultured in thioglycolate broth. The serial dilution method was used to evaluate Minimum Inhibitory Concentration (MIC). The tubes which were sensitive to MIC were plated and incubated for 24 hours. The colony count was done to determine the Minimum Bactericidal Concentration (MBC). Depending on the obtained concentrations, Boswellia serrata Roxb. gel was formulated in five concentrations and the physicochemical properties were evaluated. The periopathogens were cultured in brain–heart infusion agar plates. A disk diffusion test was performed to determine the zone of inhibition. Results: Boswellia serrata Roxb. impeded the growth of the selected periopathogens in a dose-dependent manner. F. nucleatum showed the maximum zone of inhibition at 3 μg/mL concentration. Conclusion: The physicochemical and antimicrobial properties of our study reveal that Boswellia serrata Roxb. gel can be used as an adjunct to non-surgical periodontal therapy (NSPT) as a topical gel or as a local drug delivery agent. Clinical significance: Periodontal diseases are primarily caused by plaque biofilm which commences with inflammation of the investing tissues of the tooth which, if left untreated, leads to progressive attachment loss. NSPT is the gold standard and indispensable phase of periodontal therapy. The insufficiency of NSPT in obliterating microbial growth in deep periodontal pockets and spurting microbial resistance to antibiotic drugs widened the array of research on botanical therapeutics. Boswellia serrata Roxb. is widely gaining popularity because of its antimicrobial properties and nary a side effect.

PDF Share
  1. Reygaert WC. An overview of the antimicrobial resistance of bacteria. AIMS Microbiol 2018;4(3):482–501. DOI: 10.3934/microbiol.2018.3.482
  2. Nadkarni KM, Nadkarni AK. Indian Materia Medica – with Ayurvedic, Unani-Tibbi, Siddha, Allopathic, Homeopathic, Naturopathic and Home remedies. Popular Prakashan Private Ltd., Bombay, India. 1999;1:142–9.
  3. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev 1999;12(4):564–582. DOI: 10.1128/CMR.12.4.564
  4. Kathpalia H, Shreya KK. Topical nanoemmigel formulation of Boswellia serrata. Indian J Pharm Sci 2018:80(2):261–267. DOI: 10.4172/pharmaceutical-sciences.1000353
  5. Lemenih M, Teketay D. Frankincense and Myrhh resources of Ethiopia:II. Medicinal and industrial uses. Ethiop J Sci 2003;26(2):161–272. DOI: 10.4314/sinet.v26i2.18213
  6. Roy NK, Deka A, Bordoloi D, et al. The potential role of boswellic acids in cancer prevention and treatment. Cancer Lett 2016;377(1):74–86. DOI: 10.1016/j.canlet.2016.04.017
  7. Goma AA, Mohamed HS, Abd-ellatief RB. Boswellic acids/Boswellia serrata extract as a potential COVID-19 therapeutic agent in the elderly. Inflammopharmacology 2021;29(4):1033–1048. DOI: 10.1007/s10787-021-00841-8
  8. Katragunta K, Siva B, Kondepudi N, et al. Estimation of Boswellic acids in herbal formulations containing Boswellia serrata extract and comprehensive characterization of secondary metabolites using UPCL-Q-Tof-MSe. J Pharm Anal 2019;9(6):414–422. DOI: 10.1016/j.jpha.2019.09.007
  9. Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci 2011;73(3):255–261. DOI: 10.4103/0250-474X.93507
  10. Theilade E, Wright WH, Jensen SB, et al. Experimental gingivitis in man. II. A longitudinal clinical and bacteriological investigation. J Periodontal Res 1966;1:1–13. DOI: 10.1111/j.1600-0765.1966.tb01842.x
  11. Da Rocha HA, Silva CF, Santiago FL, et al. Local drug delivery systems in the treatment of periodontitis: a literature review. J Int Acad Periodontol 2015;17(3):82–90.
  12. Avinash S, Gowda DV, Suresh J, et al. Formulation and evaluation of topical gel using Eupatorium glandulosum michx for wound healing activity. DerPharmacia Lettre 2016;8(9):255–266.
  13. Ganganna A, Rudariah CB, Rao R, et al. Antibacterial activity of melatonin against prime periodontal pathogens: an in vitro study. J Int Oral Health 2021;13(2):164–168. DOI: 10.4103/jioh.jioh_225_20
  14. Page RC, Offenbacher S, Schroeder HE, et al. Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000 1997;14:216–248. DOI: 10.1111/j.1600-0757.1997.tb00199.x
  15. Socransky SS, Haffajee AD. The Bacterial etiology of destructive periodontal disease: current concepts. J Periodontol 1992;63 Suppl 4S:322–331. DOI: 10.1902/jop.1992.63.4s.322
  16. Slots J, Rams TE. New views on periodontal microbiota in special patient categories. J Clin Periodontol 1991;18(6):411–420. DOI: 10.1111/j.1600-051x.1991.tb02309.x
  17. Bomdyal RS, Shah MU, Doshi YS, et al. Antibacterial activity of curcumin (turmeric) against periopathogens-An in vitro evaluation. J Adv Clin Res Insights 2017;4:175–80. DOI: 10.15713/ins.jcri.188
  18. Signat B, Roques C, Poulet P, et al. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol 2011;13(2):25–36.
  19. Raja AF, Ali F, Khan IA, et al. Acetyl-11-keto-β-boswellic acid (AKBA); targeting oral cavity pathogens. BMC Res Notes 2011;4:406. DOI: 10.1186/1756-0500-4-406
  20. Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in the treatment of osteoarthritis of knee- a randomized double blind placebo controlled trial. Phytomedicine 2003;10(1):3–7. DOI: 10.1078/094471103321648593
  21. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011;50(6):349–369. DOI: 10.2165/11586800-000000000-00000
  22. Maraghehpour B, Khayamzadeh M, Najaf S, et al. Traditionally used herbal medicines with antibacterial efect on Aggegatibacter actinomycetemcomitans: Boswellia serrata and Nigella sativa. J Indian Soc Periodontol 2016;20(6):603–607. DOI: 10.4103/jisp.jisp_12_17
  23. Alluri VK, Dodda S, Kilari EK, et al. Toxicological Assessment of a Standardized Boswellia serrata Gum Resin Extract. Int J Toxicol 2019;38(5):423–435. DOI: 10.1177/1091581819858069
  24. Gomaa AA, Makboul RM, Al-Mokhtar MA, et al. Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines. Biomed Pharmacother 2019;109:281–292. DOI: 10.1016/j.biopha.2018.10.056
  25. Samani MK, Mahmoodian H, Moghadamnia AA, et al. The effect of Frankiscense in the treatment of moderate plaque-induced gingivitis: a double blinded randomized clinical trial. Daru 2011;19(4):288–294.
  26. Khoshbakht Z, Khashabi E, Khodaie L, et al. Evaluation of herbal mouthwashes containing Zataria Multiflora boiss, Frankinscense and combination therapy on patients with gingivitis: A double blind, randomized, controlled, clinical trial. Galen Med J 2019;8:e1366. DOI: 10.31661/gmj.v8i0.1366
  27. Chande N, McDonald JW, MacDonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev 2008;(1):CD003575. DOI: 10.1002/14651858.cd003575.pub2
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.